AMPE:NYE-Ampio Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 1.74

Change

+0.01 (+0.58)%

Market Cap

USD 0.35B

Volume

0.71M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.90 (-0.88%)

USD177.33B 34.78 3.79
BHVN Biohaven Pharmaceutical Holdin..

-0.57 (-0.42%)

USD8.80B N/A N/A
RCUS Arcus Biosciences Inc

+0.03 (+0.08%)

USD2.51B N/A N/A
ADCT ADC Therapeutics SA

+1.19 (+4.23%)

USD2.21B -99,999.99 N/A
MYOV Myovant Sciences Ltd

+0.18 (+0.81%)

USD2.03B N/A N/A
ZYME Zymeworks Inc

+0.25 (+0.81%)

USD1.53B 300.20 N/A
RFL Rafael Holdings Inc

+0.53 (+1.48%)

USD0.73B N/A N/A
AMAM Ambrx Biopharma Inc.

-0.91 (-6.10%)

USD0.62B N/A N/A
BTX Brooklyn ImmunoTherapeutics In..

+0.09 (+0.93%)

USD0.60B 2.32 N/A
CVM CEL-SCI Corporation

+0.10 (+0.85%)

USD0.51B N/A N/A

ETFs Containing AMPE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.43% 50% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.43% 50% F 46% F
Trailing 12 Months  
Capital Gain 105.84% 81% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.84% 81% B- 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 83.46% 86% B 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.46% 86% B 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 96.62% 25% F 7% F
Risk Adjusted Return 86.37% 93% A 86% B
Market Capitalization 0.35B 63% D 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.87 33% F 27% F
Price/Book Ratio 16.15 18% F 6% F
Price / Cash Flow Ratio -23.54 87% B+ 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -113.89% 30% F 11% F
Return on Invested Capital -132.20% 31% F 1% F
Return on Assets -47.65% 21% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 17.41 10% F 2% F
Short Percent 12.66% 27% F 25% F
Beta 1.77 40% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.